Abstract
The alkaloid nicotine, a major addictive component of tobacco, exerts anti-inflammatory and immunemodulating activities on multiple cell types, such as T cells, B cells, dendritic cells, mononuclear phagocytes and polymorphonuclear leukocytes, in lung, spleen, liver, kidney and gastrointestinal tract. In addition, nicotine may blunt pro-inflammatory cytokine release, with prominent effects on T helper type 1 (Th1) and Th17 cytokines. The nonneuronal α7-nicotinic cholinergic receptors are a primary target for nicotine through the JAK2 and STAT3/NF-κB pathways, ultimately mediating the inhibition of pro-inflammatory gene transcription. The present paper reviews the growing evidence in favor of detrimental as well as beneficial effects of nicotine and other α7-nicotininc receptor agonists in pre-clinical models of organ-specific and systemic inflammatory and autoimmune diseases. These data may portend favorable implications for the targeted treatment of chronic and debilitating human disorders, such as diabetes, arthritis, asthma and inflammatory bowel disease, with α7-selective ligands.
Keywords: Nicotinic Receptors, immunity, inflammation, cytokines, cholinergic, anti-inflammatory, autoimmune encephalomyelitis, allergic asthma, arthritis, diabetes
Current Drug Targets
Title:The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Volume: 13 Issue: 5
Author(s): Perla Filippini, Alfredo Cesario, Massimo Fini, Franco Locatelli, Sergio Rutella
Affiliation:
Keywords: Nicotinic Receptors, immunity, inflammation, cytokines, cholinergic, anti-inflammatory, autoimmune encephalomyelitis, allergic asthma, arthritis, diabetes
Abstract: The alkaloid nicotine, a major addictive component of tobacco, exerts anti-inflammatory and immunemodulating activities on multiple cell types, such as T cells, B cells, dendritic cells, mononuclear phagocytes and polymorphonuclear leukocytes, in lung, spleen, liver, kidney and gastrointestinal tract. In addition, nicotine may blunt pro-inflammatory cytokine release, with prominent effects on T helper type 1 (Th1) and Th17 cytokines. The nonneuronal α7-nicotinic cholinergic receptors are a primary target for nicotine through the JAK2 and STAT3/NF-κB pathways, ultimately mediating the inhibition of pro-inflammatory gene transcription. The present paper reviews the growing evidence in favor of detrimental as well as beneficial effects of nicotine and other α7-nicotininc receptor agonists in pre-clinical models of organ-specific and systemic inflammatory and autoimmune diseases. These data may portend favorable implications for the targeted treatment of chronic and debilitating human disorders, such as diabetes, arthritis, asthma and inflammatory bowel disease, with α7-selective ligands.
Export Options
About this article
Cite this article as:
Perla Filippini, Alfredo Cesario, Massimo Fini, Franco Locatelli, Sergio Rutella , The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800399008
DOI https://dx.doi.org/10.2174/138945012800399008 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obesity and Diabetes Gene Discovery Approaches
Current Pharmaceutical Design Integrins in Pulmonary Inflammatory Diseases
Current Pharmaceutical Design Editorial [Hot Topic: An Update on Neurotrophins (Guest Editor: Celia Duarte Cruz)]
Current Neuropharmacology Mast Cell-IgE-and Mast Cell-Structural Cell Interactions in Allergic Airway Disease
Current Drug Targets - Inflammation & Allergy Prevalence, Presentation and Outcome of Secondary Bloodstream Infections among COVID-19 Patients
Infectious Disorders - Drug Targets Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design Beta-2 Agonists in Asthma: Medicine or Murderer?
Current Respiratory Medicine Reviews The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds Perinatal Vitamin D Deficiency and Childhood Asthma: A Molecular Perspective
Current Respiratory Medicine Reviews Mobile Phone Based Health Care Technology
Recent Patents on Biomedical Engineering (Discontinued) The Effect of Flavonoids on Allergic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prostaglandins Pathway as a Possible Biological Link Between Cancer and Major Depression
Current Angiogenesis (Discontinued) Diagnosis and Treatment of Pulmonary Fungal Infections in Critically Ill Patients
Current Respiratory Medicine Reviews Experimental Phage Therapies in Companion Animals with A Historical Review
Current Reviews in Clinical and Experimental Pharmacology Physical Means of Stratum Corneum Barrier Manipulation to Enhance Transdermal Drug Delivery
Current Drug Delivery Immune Stimulatory Strategies for the Prevention and Treatment of Asthma
Current Pharmaceutical Design Nasal Air-Conditioning During Breathing Therapy
Current Respiratory Medicine Reviews Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Current Medicinal Chemistry Bioinformatics and Therapeutic Insights on Proteins in Royal Jelly
Current Proteomics Recent Approaches on Novel Topical Delivery Systems for Atopic Dermatitis Treatment
Recent Patents on Drug Delivery & Formulation